1.Advances in Dyslipidaemia Treatments: Focusing on ApoC3 and ANGPTL3 Inhibitors

Tomlinson, Brian, Wu     More...

Tomlinson, Brian, Wu, Qian Yan, Zhong, Yi Ming, Li, Yan Hong     Less

Journal of Lipid and Atherosclerosis[2287-2892], Published 2024, Volume 13, Issue 1, Pages 2-20

收錄情况： SCOPUS

2.Circulating metabolomic markers linking diabetic kidney disease and incident cardiovascular disease in type 2 diabetes: analyses from the Hong Kong Diabetes Biobank

Jin, Q, Lau, ESH, Lu     More...

Jin, Q, Lau, ESH, Luk, AO, Tam, CHT, Ozaki, R, Lim, CKP, Wu, HJ, Chow, EYK, Kong, APS, Lee, HM, Fan, BQ, Ng, ACW, Jiang, GZ, Lee, KF, Siu, SC, Hui, GC, Tsang, CC, Lau, KP, Leung, JY, Tsang, MW, Cheung, EYN, Kam, G, Lau, IT, Li, JK, Yeung, VTF, Lau, E, Lo     Less

DIABETOLOGIA[0012-186X], Published 2024, Volume 67, Issue 5, Pages 837-849

收錄情况： WOS SCOPUS

WOS核心合集引用: 3  2023影響因子:  8.4 

3.Genetic drivers of heterogeneity in type 2 diabetes pathophysiology

    More...

    Less

NATURE[0028-0836], Published 2024, Volume 627, Issue 8003, Pages 347-357

收錄情况： WOS SCOPUS

WOS核心合集引用: 44  2023影響因子:  50.5 

4.Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes: an update

Tomlinson, B, Chan,     More...

Tomlinson, B, Chan, P     Less

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY[1742-5255], Published 2024, Volume 20, Issue 4, Pages 175-179

收錄情况： WOS SCOPUS

WOS核心合集引用: 0  2023影響因子:  3.9 

5.The maximum dose of atorvastatin and simvastatin as well as rosuvastatin should be restricted in East Asians

Tomlinson, B, Chow,     More...

Tomlinson, B, Chow, E     Less

HONG KONG MEDICAL JOURNAL[1024-2708], Published 2024, Volume 30, Issue 2, Pages 184-185

收錄情况： WOS SCOPUS

WOS核心合集引用: 0  2023影響因子:  3.1 

6.Genetic factors related to aspirin resistance using the Multiplate® device in Hong Kong Chinese patients with stable coronary heart disease

Zeng, WW, Chu, TTW,     More...

Zeng, WW, Chu, TTW, Chow, EYK, Hu, M, Fok, BSP, Chan, JCN, Yan, BPY, Tomlinson, B     Less

HELIYON[2405-8440], Published 2024, Volume 10, Issue 14,

收錄情况： WOS SCOPUS

WOS核心合集引用: 0  2023影響因子:  3.4 

7.Therapeutic efficacy of ECs Foxp1 targeting Hif1α-Hk2 α-Hk2 glycolysis signal to restrict angiogenesis

Pi, JJ, Chang, H, Ch     More...

Pi, JJ, Chang, H, Chen, XL, Pan, WQ, Zhang, Q, Zhuang, T, Liu, JW, Wang, HK, Tomlinson, B, Chan, PL, Cheng, Y, Yu, ZR, Zhang, L, Zhao, ZL, Liu, ZM, Liu, J, Zhang, YZ     Less

REDOX BIOLOGY[2213-2317], Published 2024, Volume 75,

收錄情况： WOS SCOPUS

WOS核心合集引用: 1  2023影響因子:  10.7 

8.Options for patients with out-of-control blood pressure: after all avenues have been exhausted

Zeng, WW, Tomlinson,     More...

Zeng, WW, Tomlinson, B     Less

EXPERT REVIEW OF CARDIOVASCULAR THERAPY[1477-9072], Published 2024,

收錄情况： WOS SCOPUS

WOS核心合集引用: 0  2023影響因子:  1.8 

9.Effects of Hawthorn Fruit Extract Drink in Chinese Patients With Mild Hypertension and/or Hyperlipidaemia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study

Zeng, WW, Chu, TTW,     More...

Zeng, WW, Chu, TTW, Fok, BSP, Ho, WKK, Chan, JCN, Tomlinson, B     Less

DOSE-RESPONSE[1559-3258], Published 2024, Volume 22, Issue 4,

收錄情况： WOS

WOS核心合集引用: 0  2023影響因子:  2.3 

10.Statin alternatives for the treatment of hypercholesterolemia - a safety evaluation

Zeng, WW, Tomlinson,     More...

Zeng, WW, Tomlinson, B     Less

EXPERT OPINION ON DRUG SAFETY[1474-0338], Published 2024,

收錄情况： WOS SCOPUS

WOS核心合集引用: 0  2023影響因子:  3.0 

More...